Press releases

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Credit Suisse Healthcare Conference on November 7, in Scottsdale, Arizona. Joe Fitzgerald, executive vice...

Boston Scientific (NYSE: BSX) today announced key data which will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled...

Marlborough, Mass. October 13, 2016) -- Boston Scientific Corporation (NYSE: BSX) today announced a worldwide call for submissions to the second annual Boston Scientific Connected Patient...

Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October...

Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike Mahoney, chief executive officer, and Dan...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The...

Boston Scientific Corporation (NYSE: BSX) announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately. Yoshiaki Fujimori is an adviser to the LIXIL Group...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 at

Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...

Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Global Healthcare Conference on June 9 in Rancho Palos Verdes. Dan Brennan, executive vice president and...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2016 Healthcare Conference on June 7, in New York City. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Precision Montage™ MRI Spinal Cord Stimulator (SCS) System after receiving approval from the U.S. Food and Drug...

Boston Scientific (NYSE: BSX) today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patient EWOLUTION...

Boston Scientific (NYSE: BSX) today announced results from the largest post-market registry for the Subcutaneous Implantable Defibrillator (S-ICD) System. Data collected from the EFFORTLESS study...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the Rhythmia™ Mapping System. The IntellaNav™ XP and the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2016 Health Care Conference on May 12, in Las Vegas. Dan Brennan, executive vice...

Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS)...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.964 billion during the first quarter ended March 31, 2016, compared to the company's guidance range for the quarter of $1.890 to...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for use in a magnetic resonance imaging (MRI) environment. The...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 41st Annual Health Care Conference on May 5, in Boston. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...

Boston Scientific (NYSE: BSX) has initiated a global, voluntary recall of all models of its Fetch™ 2 Aspiration Catheter, a thrombectomy catheter used during procedures to remove small blood...

Boston Scientific does not use “counterfeit” or “adulterated” materials in our medical devices. The company rejects the allegations in the petition to the Food and Drug Administration...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2016 on Wednesday, April 27,...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 15th Annual Needham Healthcare Conference on April 12, in New York City. Susie Lisa, vice president, Investor...

Boston Scientific (NYSE: BSX) today announced key data presentations spanning its interventional cardiology, rhythm management and structural heart portfolios, that will be featured at the...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from...

Boston Scientific Corporation (NYSE: BSX) and Mayo Clinic today announced a continuing collaboration where the two organizations share intellectual property and stimulate the rapid development of...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Blazer™ Open-Irrigated (OI) radiofrequency ablation catheter. The Blazer OI catheter has been...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Health Care Conference on March 15, in Miami Beach. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) announced today a number of changes to the leadership and membership of its Board of Directors. Pete M. Nicholas, the company's co-founder and chairman of...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen & Co. 36th Annual Health Care Conference on March 8, in Boston. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV) leads. The FDA approval of the quadripolar leads,...

Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...

Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant...

MARLBOROUGH, Mass. (February 1, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced that Bronchial Thermoplasty (BT) delivered by the Alair™ System is now available to Tufts...

Boston Scientific Corporation (NYSE: BSX) and Accenture (NYSE: ACN) have developed a cloud-based, data-driven digital health solution for hospitals that is designed to help improve patient...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Partners 5th Annual Global Healthcare Conference on February 10, in New York City. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVue™ Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...